Antiangiogenic Therapy for High-Grade, Recurrent Brain Tumors
Name of the Trial
Phase II Study of LY317615 in Patients with Recurrent High-Grade Gliomas (NCI-03-C-0018). See the protocol summary.
Dr.Fine, chief of the Neuro-Oncology Branch at NCI's Center for Cancer Research.
Why This Trial Is Important
Glioma, a type of brain cancer, is the most common primary tumor of the central nervous system. Surgery is often used to treat gliomas. Sometimes, however, surgery fails to cure the disease. In these cases, doctors may turn to radiation or chemotherapy.
A chemotherapy drug known as LY317615 may stop the growth of gliomas by halting blood flow to the tumor, a process called antiangiogenesis. This trial seeks to establish the tumor-fighting ability of LY317615 in patients with high-grade, recurrent gliomas and assess the side effects the drug may have on patients.
"Recurrent malignant glioma is a desperate disease for which there are very few adequate treatments," said Dr. Fine. "This drug could be a highly potent therapy, though, because preclinical studies show that it may have both an indirect antiangiogenic effect as well as a direct cancer-killing effect on gliomas. Early results have already demonstrated the ability of LY317615 to stop the growth and shrink the tumor in some patients.
"Additionally, the trials of LY317615 to date have shown that the agent has minimal side effects," he said.
This clinical trial is closed to further patient accrual. To find other brain tumor clinical trials, search the NCI's database of clinical trials or call the NCI Clinical Studies Support Center at 1-888-NCI-1937. This call is toll-free and confidential.
Fine HA, Kim L, Royce C, et al.: Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. [Abstract] J Clin Oncol 23 (Suppl 16): A-1504, 115s, 2005.